Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients

Jagota, Priya; Kaewwilai, Lalita; Boonrod, Nonglak; Singmaneesakulchai, Surat; Boonpang, Kamolwan; Sringean, Jirada; Jitkritsadakul, Onanong; Petchrutchatachart, Sitthi

doi:10.7916/d8736r2h

Cited by 6 publications

(1 citation statement)

References 20 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Other types of BoNT have been recently developed but have not been FDA approved. These include letibot-ulinumtoxinA (Botulax), 35 NeubotulinumtoxinA (Neuronox), 36 and Prabotulinumtoxin A (Daewoong), 37 . However, there is limited research investigating these forms of BoNT for treating post-stroke arm dysfunction compared to the four approved forms.…”

Section: Effect Of Botulinum Toxin By Typementioning

confidence: 99%

The Effectiveness of Botulinum Toxin Injections to Treat Post-Stroke Arm Dysfunction

Tsai,

Sullivan

2023

J Stud Res

View full text Add to dashboard Cite

This review was written to determine the effectiveness of Botulinum Toxin (BoNT) as a treatment for upper extremity dysfunction in post-stroke patients. As most patients survive a stroke, many are burdened with disability and impaired limb function. Seventy percent of stroke patients experience motor dysfunction in the arm, with thirty percent of patients suffering from upper extremity spasticity. Spasticity is a speed-dependent condition where certain muscles are abnormally stiff, resulting in involuntary contraction when the spastic muscle is used. BoNT treatment includes injections in localized muscles and is primarily used to treat spasticity by temporarily paralyzing the injected muscle. Seven systematic reviews/meta-analyses and ten randomized-controlled trials were used to determine the effectiveness of BoNT in post-stroke patients. Overall, BoNT is effective in reducing spasticity and may be effective in reducing pain. However, its ability to improve motor function is still unclear. In addition, there is mixed evidence on the most effective way to administer BoNT treatment, such as the proper dosage or combining BoNT with another therapy. The treatment’s effectiveness is well documented in the chronic stage of stroke but less so in the acute and subacute stages. More research is needed to determine the potential adverse effects of long-term exposure to BoNT and the most appropriate dose to administer.

show abstract

Section: Effect Of Botulinum Toxin By Typementioning

confidence: 99%

The Effectiveness of Botulinum Toxin Injections to Treat Post-Stroke Arm Dysfunction

Tsai,

Sullivan

2023

J Stud Res

View full text Add to dashboard Cite

show abstract

Improvement of quality of life and mental health in patients with spasmodic torticollis after microvascular decompression

et al. 2019

Clinical Neurology and Neurosurgery

View full text Add to dashboard Cite

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Kongsaengdao

Maneeton

2018

NDT

View full text Add to dashboard Cite

BackgroundThe short-term quality of life (QoL) in cervical dystonia (CD) after treating with abobotulinum toxin A (Abo-BTX A) and neubotulinum toxin A (Neu-BTX A) have been studied in Thai CD patients. However; the long-term study has not been published.ObjectiveThe aim of the present study was to determine long-term improvement of the health-related quality of life (HRQoL) after eight injections of Abo-BTX A over 2 years in CD patients.Patients and methodsA 2-year prospective study on the QoL of CD patients, as measured by HRQoL, before and after receiving eight injections of Abo-BTX A at 3-month intervals over a 2-year treatment period was performed. The disease-specific HRQoL was assessed before and after the treatment by using the Cervical Dystonia Impact Profile-58 (CDIP-58) questionnaire. The general HRQoL was assessed by using the Medical Outcomes 36-Item Short Form Health Survey (SF-36), while depressive disorder screening was assessed by using the Center of Epidemiologic Studies-Depression (CES-D) questionnaire. The SF-36 and CES-D questionnaire were administered before treatment and every 3 months before the next injection for a 2-year period.ResultsA total of 20 CD patients were enrolled from January 2013 to December 2015. CDIP-58 showed a significant improvement after long-term injections of Abo-BTX A in all domains (P < 0.001). However, only vitality domain of SF-36, which assessed general HRQoL, showed a significant improvement after long-term injections (P = 0.037). There was no prevalence of depressive disorder in all patients (CES-D score <20) in this study.ConclusionThe Abo-BTX A injections at 3-month intervals over a 2-year period improved the CDIP-58 scores, which assess disease-specific HRQoL, as well as an increased vitality domain of general HRQoL. No patient suffered from depression in this study.

show abstract

Impact of Neu-botulinumtoxinA on the Severity and Quality of Life of Cervical Dystonia Patients

Cited by 6 publications

References 20 publications

The Effectiveness of Botulinum Toxin Injections to Treat Post-Stroke Arm Dysfunction

The Effectiveness of Botulinum Toxin Injections to Treat Post-Stroke Arm Dysfunction

Improvement of quality of life and mental health in patients with spasmodic torticollis after microvascular decompression

Long-term quality of life in cervical dystonia after treatment with abobotulinum toxin A: a 2-year prospective study

Contact Info

Product

Resources

About